Why Aurora Cannabis’s (ACB) Stock Price Fell 16% in December

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) stock price continues to fall, as the cannabis industry remains in disarray.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

Cannabis stocks like Aurora Cannabis (TSX:ACB)(NYSE:ACB) had their heads handed to them in December once again, as the downward spiral continues.  When a bubble bursts, it falls hard, and Aurora Cannabis’s stock price is a prime example of this. Down 16% in December, 65% in the last year, and 81% from its highs, Aurora Cannabis stock still carries too much risk and uncertainty for investors.

So, why did Aurora Cannabis’s stock price fall again in December, and what, if anything, should investors do at this point?

Aurora Cannabis still reeling from disappointing results

The first quarter of fiscal 2020 turned out to be another disappointing quarter, as revenue growth continued to slow and as losses continued to mount. Revenue declined 24% sequentially in the quarter, as medical cannabis revenue increased a mere 3%, and Canadian consumer cannabis revenue declined 33%, as distribution and regulatory headwinds played havoc on the cannabis industry.

As per the company’s release, “provincial ordering slowed considerably during the summer as distributors worked through inventories and as the industry was impacted by the slow pace of retail store licensing.”

Executive shakeup amid high inventory levels

As the company moves forward, it has been making changes at the top. Chief Corporate Officer Cam Battley was asked to step down from his role at the company, as Aurora Cannabis and the industry in general tries to recover and move forward from the carnage brought about by excessive inventory levels and “weaker-than-expected” market growth.

The focus now will be on strengthening the balance sheet and cutting capital expenditures to a more sustainable level that takes into consideration the financial health (or lack thereof) of the business.

The bursting of a bubble

I have repeatedly warned fellow Fool investors that investing in the cannabis sector when many of the cannabis stocks were trading at multiples of north of 100 times sales was more of a gamble than an investment, that the stocks had reached bubble territory, and that it was only a matter of time before the bubble burst.

In December, Aurora Cannabis’s stock price continued to plummet, as the bursting of the bubble continued. There will be a time when these cannabis stocks represent value — an attractive risk/reward tradeoff — but the time in not now, as there remains much uncertainty and big downside in these growth stocks.

Earnings estimates for Aurora Cannabis stock have been slashed quite dramatically over the last year. The 2022 estimate was cut from $0.34 earlier this year to the current consensus estimate calling for a net loss of $0.01 per share.

Foolish final thoughts

The one silver lining here is that Aurora Cannabis stock price is now trading at a price-to-sales multiple of eight times. It is pretty much out of crazy bubble territory. It will take time for the stock recover, and it is still a very risky investment, but at least Aurora Cannabis has more than $2 billion in cash to take it through the upcoming tumultuous months.

Finally, I would like to remind Foolish investors of our belief in holding great businesses for the long term. While this belief remains intact, we are also aware that, sometimes, short-term stock price movements create opportunities to create wealth. By blending this long-term focus with a keen eye for short-term stock mispricings, we can use both strategies in harmony, and our quest for financial freedom can be fulfilled.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »